Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load. 1999

J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
Institute of Microbiology, University Medical School, Debrecen, Hungary.

OBJECTIVE We have previously demonstrated that complement-mediated antibody-dependent enhancement (C-ADE) of HIV-1 infection correlates with accelerated immunosuppression and disease progression in HIV-1-infected individuals. In the present work the relationship between C-ADE and plasma HIV-1 RNA concentrations was studied to determine the effect of C-ADE on viral replication. METHODS Three studies were performed: (a) C-ADE and HIV-1 RNA concentrations were determined in the serum and plasma aliquots taken at the same time from 98 HIV patients, mostly in the advanced stage of the disease; (b) the above two parameters as well as HIV enzyme-linked immunosorbent assay (ELISA)-reactive antibodies (Abbott HIV 1/2 test), and p24 antigen levels (Abbott antigen test; Abbott, Delkenheim, Germany) were determined in four seroconversion panels purchased from the Boston Biomedica firm; (c) changes of HIV-1 RNA concentration and C-ADE during a 17 month follow-up period were determined in 18 HIV-infected patients. C-ADE was measured by the method previously established in our laboratories. The results were expressed by an enhancement/neutralization index (E/NI). HIV-1 RNA levels were determined with the Amplicor monitor kit (Roche, Basel, Switzerland), and in some experiments with the nucleic acid sequence based amplification (Organon Teknika, Turnhout, Belgium) kits. RESULTS (a) We found a highly significant (P<0.0001) positive correlation between E/NI values reflecting the extent of HIV-1 infection enhancement and plasma HIV-1 RNA levels. Both E/NI and HIV-1 RNA levels negatively correlated to the CD4 cell counts. (b) C-ADE was first detected just before, or concomitantly with, seroconversion in 4/4 seroconversion panels. (c) Both E/NI values and HIV-1 RNA levels significantly (P<0.001) increased during a 17 month observation period in 18 HIV-infected patients. CONCLUSIONS We found strong association between the extent of the complement-mediated antibody-dependent enhancement of HIV-1 infection and the plasma viral load in HIV patients. On the basis of these findings, C-ADE correlates with HIV replication in vivo, and potentially contributes to the progression of HIV disease.

UI MeSH Term Description Entries
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
April 1990, Virology,
J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
September 1997, AIDS (London, England),
J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
March 2005, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists,
J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
October 1994, Journal of acquired immune deficiency syndromes,
J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
April 1989, Antiviral research,
J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
January 2004, AIDS (London, England),
J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
January 2013, Annals of clinical and laboratory science,
J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
August 1990, AIDS research and human retroviruses,
J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
June 1988, Lancet (London, England),
J Szabó, and Z Prohászka, and F D Tóth, and A Gyuris, and J Segesdi, and D Bánhegyi, and E Ujhelyi, and J Minárovits, and G Füst
March 1991, AIDS (London, England),
Copied contents to your clipboard!